Update on polymyalgia rheumatica

Nicolò Pipitone, Carlo Salvarani

Research output: Contribution to journalArticle

Abstract

Polymyalgia rheumatica is an inflammatory disease of unknown etiology affecting individuals aged fifty years and older, mainly of Caucasian ethnicity. Polymyalgia rheumatica is associated with giant cell arteritis more frequently than expected by chance alone. In both conditions, females are affected two to three times more often than males. The clinical hallmark manifestations of polymyalgia rheumatica are aching and morning stiffness in the shoulder girdle and often in the pelvic girdle and neck. Serum inflammatory markers are typically elevated, while the most consistent abnormal finding on imaging studies is bursitis in the symptomatic areas. A dramatic response to glucocorticoids is characteristic of polymyalgia rheumatica. Many patients are able to discontinue glucocorticoids six months to two years after the onset of clinical symptoms, but some patients may require longstanding glucocorticoid treatment. Glucocorticoid-sparing agents may be helpful in patients with chronic relapsing courses and those at high risk of glucocorticoid-related adverse events.

Original languageEnglish
Pages (from-to)583-589
Number of pages7
JournalEuropean Journal of Internal Medicine
Volume24
Issue number7
DOIs
Publication statusPublished - Oct 2013

Fingerprint

Polymyalgia Rheumatica
Glucocorticoids
Bursitis
Giant Cell Arteritis
Neck
Biomarkers

Keywords

  • Bursitis
  • Elderly
  • Glucocorticoids
  • Polymyalgia rheumatica
  • TNF-α inhibitors
  • Tocilizumab

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Update on polymyalgia rheumatica. / Pipitone, Nicolò; Salvarani, Carlo.

In: European Journal of Internal Medicine, Vol. 24, No. 7, 10.2013, p. 583-589.

Research output: Contribution to journalArticle

Pipitone, Nicolò ; Salvarani, Carlo. / Update on polymyalgia rheumatica. In: European Journal of Internal Medicine. 2013 ; Vol. 24, No. 7. pp. 583-589.
@article{e404219ca8b64262b148cdecd885fc1b,
title = "Update on polymyalgia rheumatica",
abstract = "Polymyalgia rheumatica is an inflammatory disease of unknown etiology affecting individuals aged fifty years and older, mainly of Caucasian ethnicity. Polymyalgia rheumatica is associated with giant cell arteritis more frequently than expected by chance alone. In both conditions, females are affected two to three times more often than males. The clinical hallmark manifestations of polymyalgia rheumatica are aching and morning stiffness in the shoulder girdle and often in the pelvic girdle and neck. Serum inflammatory markers are typically elevated, while the most consistent abnormal finding on imaging studies is bursitis in the symptomatic areas. A dramatic response to glucocorticoids is characteristic of polymyalgia rheumatica. Many patients are able to discontinue glucocorticoids six months to two years after the onset of clinical symptoms, but some patients may require longstanding glucocorticoid treatment. Glucocorticoid-sparing agents may be helpful in patients with chronic relapsing courses and those at high risk of glucocorticoid-related adverse events.",
keywords = "Bursitis, Elderly, Glucocorticoids, Polymyalgia rheumatica, TNF-α inhibitors, Tocilizumab",
author = "Nicol{\`o} Pipitone and Carlo Salvarani",
year = "2013",
month = "10",
doi = "10.1016/j.ejim.2013.03.003",
language = "English",
volume = "24",
pages = "583--589",
journal = "European Journal of Internal Medicine",
issn = "0953-6205",
publisher = "Elsevier B.V.",
number = "7",

}

TY - JOUR

T1 - Update on polymyalgia rheumatica

AU - Pipitone, Nicolò

AU - Salvarani, Carlo

PY - 2013/10

Y1 - 2013/10

N2 - Polymyalgia rheumatica is an inflammatory disease of unknown etiology affecting individuals aged fifty years and older, mainly of Caucasian ethnicity. Polymyalgia rheumatica is associated with giant cell arteritis more frequently than expected by chance alone. In both conditions, females are affected two to three times more often than males. The clinical hallmark manifestations of polymyalgia rheumatica are aching and morning stiffness in the shoulder girdle and often in the pelvic girdle and neck. Serum inflammatory markers are typically elevated, while the most consistent abnormal finding on imaging studies is bursitis in the symptomatic areas. A dramatic response to glucocorticoids is characteristic of polymyalgia rheumatica. Many patients are able to discontinue glucocorticoids six months to two years after the onset of clinical symptoms, but some patients may require longstanding glucocorticoid treatment. Glucocorticoid-sparing agents may be helpful in patients with chronic relapsing courses and those at high risk of glucocorticoid-related adverse events.

AB - Polymyalgia rheumatica is an inflammatory disease of unknown etiology affecting individuals aged fifty years and older, mainly of Caucasian ethnicity. Polymyalgia rheumatica is associated with giant cell arteritis more frequently than expected by chance alone. In both conditions, females are affected two to three times more often than males. The clinical hallmark manifestations of polymyalgia rheumatica are aching and morning stiffness in the shoulder girdle and often in the pelvic girdle and neck. Serum inflammatory markers are typically elevated, while the most consistent abnormal finding on imaging studies is bursitis in the symptomatic areas. A dramatic response to glucocorticoids is characteristic of polymyalgia rheumatica. Many patients are able to discontinue glucocorticoids six months to two years after the onset of clinical symptoms, but some patients may require longstanding glucocorticoid treatment. Glucocorticoid-sparing agents may be helpful in patients with chronic relapsing courses and those at high risk of glucocorticoid-related adverse events.

KW - Bursitis

KW - Elderly

KW - Glucocorticoids

KW - Polymyalgia rheumatica

KW - TNF-α inhibitors

KW - Tocilizumab

UR - http://www.scopus.com/inward/record.url?scp=84884283485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884283485&partnerID=8YFLogxK

U2 - 10.1016/j.ejim.2013.03.003

DO - 10.1016/j.ejim.2013.03.003

M3 - Article

C2 - 23579169

AN - SCOPUS:84884283485

VL - 24

SP - 583

EP - 589

JO - European Journal of Internal Medicine

JF - European Journal of Internal Medicine

SN - 0953-6205

IS - 7

ER -